This company listing is no longer active
ONXEO Stock Overview
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.30 |
| 52 Week High | €4.21 |
| 52 Week Low | €1.17 |
| Beta | 1.26 |
| 1 Month Change | -23.08% |
| 3 Month Change | -48.21% |
| 1 Year Change | -63.38% |
| 3 Year Change | -70.12% |
| 5 Year Change | -85.63% |
| Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONXEO | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 5.7% | -0.2% | -0.06% |
| 1Y | -63.4% | -13.7% | 21.3% |
Return vs Industry: ONXEO underperformed the Danish Biotechs industry which returned 23.5% over the past year.
Return vs Market: ONXEO underperformed the Danish Market which returned 3.8% over the past year.
Price Volatility
| ONXEO volatility | |
|---|---|
| ONXEO Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.5% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: ONXEO's share price has been volatile over the past 3 months.
Volatility Over Time: ONXEO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 36 | Shefali Agarwal | valeriotx.com |
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Valerio Therapeutics Société anonyme Fundamentals Summary
| ONXEO fundamental statistics | |
|---|---|
| Market cap | kr.175.26m |
| Earnings (TTM) | -kr.94.07m |
| Revenue (TTM) | kr.25.85m |
6.8x
P/S Ratio-1.9x
P/E RatioIs ONXEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONXEO income statement (TTM) | |
|---|---|
| Revenue | €3.47m |
| Cost of Revenue | €416.00k |
| Gross Profit | €3.06m |
| Other Expenses | €15.70m |
| Earnings | -€12.64m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 88.02% |
| Net Profit Margin | -363.89% |
| Debt/Equity Ratio | 44.0% |
How did ONXEO perform over the long term?
See historical performance and comparison